Features of acute rejection in dual kidney transplant have not been studied. The aim of this study is to compare acute rejections in dual kidney transplant recipients from elderly donors on different immunosuppressive protocols. Sixty-nine patients were evaluated: 28 received calcineurin inhibitorbased (group 1) and 41 received calcineurin inhibitor-free immunosuppression (group 2). Histology of all donor kidneys was evaluated before implantation. All rejections showed tubulitis in both groups, and were classified as T cell-mediated acute rejections. Incidence and Banff grade of rejections in the two groups were not significantly different. Late rejections however, were observed in group 1 (P < 0.01) whereas steroid-resistant rejections occurred in group 2 (P < 0.03). C4d deposition was only observed in group 2. Occurrence of acute rejection was significantly associated with graft loss due to interstitial fibrosis/tubular atrophy in both groups. In group 1 mean serum creatinine levels of patients with rejections at six months and one year were higher than those of patients without rejections (P < 0.03 and P < 0.009, respectively). In group 2 they were higher at six months (P < 0.01) but not at one year. In addition, graft loss due to interstitial fibrosis/tubular atrophy occurred in 3/28 patients in group 1 (10.7%, OR= 1.95, 95%CI 1.02-3.71), and in 1/41 patients in group 2 (2.4%, OR= 0.41, 95%CI 0.07-2.24). Taken together these results suggest better renal function in patients on calcineurin inhibitorfree immunosuppression. In conclusion, acute rejections were detrimental irrespective of the type of immunosuppression, but different features were observed with each therapy. A tailored approach should be advantageous for prevention and treatment of acute rejections.
and others (2) (3) . IF/TA can begin in the first year following transplant due to ischemia-reperfusion damage and immunologic causes, and increases later on, likely as a consequence of chronic CI-toxicity (1) . Acute rejection usually occurs in the first year after transplant, causing variable degrees of tissue injury. How it impacts the outcome of the graft is unclear, and features such as type, number, timing and severity, have been proposed to influence long-term prognosis (3) (4) (5) (6) . Acute rejection can be antibody-mediated or T-cell mediated (ATCMR). Its histological severity can be evaluated in a semi-quantitative manner using the Banff classification which divides ATCMR into tubulo-interstitial (borderline and type I) and vascular (type II and III) (2, 7) . Tubulo-interstitial ATCMR is the most frequent type of acute rejection (1) (2) (3) (4) (5) (6) .
Antibody-mediated rejection is caused by circulating antibodies to donor endothelial alloantigens. It can be steroid resistant and has a poorer prognosis (8) (9) (10) . ATCMR can exhibit an antibody-mediated component (8) (9) . The C4d fragment of the C4 complement component is released during activation of the classical complement pathway that follows an antigenantibody reaction. Its deposition along endothelial cells of peritubular capillaries (PTC) is associated with circulating donor-specific antibodies, (8, (10) (11) and is considered a marker of antibody-mediated reaction. Many centers, however, do not have the facilities to detect circulating anti-donor antibodies. In addition, it can be difficult to find low antibody levels. A diagnosis of suspicious antibody-mediated reaction can be formulated when C4d deposition is associated with one of the following tissue changes: acute tubular necrosis, glomerulitis and polymorphonuclear leukocytes or monocytes in PTC or arteritis (2) . Endothelial damage caused by antibodies can increase the severity of ATCMR. In line with this concept, diffuse C4d deposition in type I ATCMR was found to be associated with IFITA (12) (13) .
Marginal kidneys from expanded criteria donors (14) are an important option to counteract the shortage of donor kidneys. Grafts from elderly donors are the most common category, and since they may possess a reduced renal reserve, two kidneys are transplanted in a single recipient, usually age-matched.
It has been recently shown that graft loss in recipients of grafts from donors over 70 years of age was higher than in recipients of grafts from donors 60 to 69 years of age (15) Calcineurin inhibitor-free immunosuppressive therapy based on sirolimus can preserve renal function and decrease the likelihood ofIF/TA (16) . Thus, in this context it might be particularly advantageous. To the best of our knowledge the impact of acute rejection in dual kidney transplant has not been addressed. A high level of immunogenicity in kidneys from elderly donors has been hypothesized in rats and in humans (17) (18) , and this could influence acute rejection features. On the other hand, recipients might be at lower immunological risk, due to their older age, which is associated with attenuated inflammatory, cellular and humoral responses. We therefore evaluated acute rejection features and outcomes in dual kidney transplant recipients from elderly donors (DKT). Moreover, we compared DKT receiving calcineurin inhibitor (CI)-based immunosuppression (group 1) with those receiving CI-free immunosuppression (group 2).
MATERIALS AND METHODS

Study subjects
Sixty-nine dual kidney transplant recipients from elderly donors (DKT) were evaluated: 28 patients undergoing transplant consecutively between October 1999 and June 2003 (mean follow up 59.7 + 28.1 months) who received CI-based immunosuppressive therapy (group 1) consisting of cyclosporine, mycophenolate mofetil (MMF) and corticosteroids; and 41 patients transplanted subsequently from April 2003 to April 2006 (mean follow up 27.0 ± 11.1 months) who received CIfree therapy (group 2) consisting of sirolimus, MMF and corticosteroids. Mean donor age was 71.9 ± 5.3 and 73.6 ± 4.0 years in groups 1 and 2, respectively. Demographics of donors and recipients and clinical data are reported in Table I . All patients had a negativepretransplant cytotoxic crossmatch. One patient in group 1 was PRA test-positive. All acute rejection episodes were associated with an increase in serum creatinine levels, documented by biopsy, and evaluated according to the Banff classification (2, 7) . T-cell mediated acute rejection (ATCMR) occurring within six months after transplantation were defined as "early," and those after six months as "late". ATCMRs were treated with methylprednisolone pulses; six were steroid resistant and anti-thymocyte globulin was administered, and in three cases plasmapheresis was also performed.
Histopathology
Biopsy of donor kidneys prior to transplant was performed in all cases. Glomerular sclerosis, interstitial fibrosis, tubular atrophy, and vascular lesions were assessed according to the scoring system by Remuzzi et al. (19) . Changes in each component received a score ranging from 0 to 3. The sum of these scores, defined as kidney score could range from 0 to 12. Kidneys with a score from 4 to 6 were considered for use in dual transplants. When one kidney had a score from 0 to 3 and the other of 4 or greater the two kidneys were transplanted in the same patient. Kidneys with a score of 7 or greater were not utilized. When one kidney had a score from 4 to 6 and the other of 7 or greater the kidneys were not used. The number of glomeruli in group 1 donor biopsies was 18.76 ± 7.8 and 18.09 ± 6.14 (right and left kidney, respectively), mean score = 3.78 ± 1.07. The number of glomeruli in group 2 donor biopsies was 16.8 ± 5.9 and 16.1 ± 5.1 (right and left kidney, respectively), mean score = 3.76 ± 1.0. Donor biopsies were evaluated also according to the Banff classification (2, 7). Post-transplant acute rejection biopsies were considered adequate when at least ten glomeruli and two arteries were present.
Serial sections were prepared from formalin-fixed, paraffin-embedded biopsies.
Hematoxylin-eosin, PAS, Heidenhain trichrome and Weigert Van Gieson stains were performed. Sections were stained for immunohistochemistry by the Envision technique (Dako, Glostrup, Denmark) using the monoclonal antibody anti-CD68 (Dako, Glostrup, Denmark) after trypsin pretreatment (Sigma, St Louis, MO, USA). Paraffin sections for detection ofC4d were stained by the Envision technique (Dako) after antigen retrieval by pressure-cooking using a po1yclonal anti-C4d antibody (Biomedica, Vienna, Austria). Primary antibodies were replaced by irrelevant matched monoclonal antibodies or non-immune serum, as appropriate, as a control for non-specific staining. For C4d staining, renal biopsies from non-transplanted patients (with unrelated pathologies) and sections showing C4d positivity due to acute antibody-mediated rejection were used as negative and positive controls, respectively. Diffuse positive staining, focal positive staining, and PTC score (number of inflammatory cells in PTC) were evaluated according to the Banff classification (2) .
IF/TA was diagnosed on explanted kidneys of patients who experienced graft loss (return to dialysis) when the degrees of chronic interstitial and tubular changes, graded according to the Banff classification (2, 7) were higher than those assessed prior to transplant.
Statistical Analysis
Results are expressed as mean ± SD. Pearson's chisquare test, and Student's t-test for non-paired data were performed for statistical analysis.
RESULTS
Evaluation ofacute rejections
Sixty-nine DKT were evaluated. Twenty-eight received CI-based immunosuppression (group 1), and 41 received CI-free therapy (group 2). There were no significant differences between the groups in terms of age of donors, age of recipients, male/ female ratio, cold ischemia time, HLA matching, and delayed graft function (Table I ). The histological mean donor kidney score was also not significantly different: 3.78 ± 1.07 in group 1 and 3.76 ± 1.0 in group 2, respectively (mean of right and left kidney scores for each donor), and 4.14 ± 1.10 in group 1 and 4.17 ± 0.94 in group 2, respectively, when the highest score for each donor was considered.
All acute rejection biopsies showed tubulitis and were classified as ATCMRs. The impact of ATCMR on the outcome in each group was evaluated. In group 1 6/28 patients experienced ATCMRs. Seven ATCMR episodes were observed: four borderline, In group 2, 7/41 patients experienced ATCMR. Eleven ATCMR episodes were observed: four borderline, five type lA, one type IE and one type II. The mean serum creatinine level was significantly higher than that of patients without ATCMRs at six months (P < 0.01) but not at one year (Fig. 1) .
Graft loss due to IFITA occurred in one of the seven patients with ATCMR (14.3%), while among patients without ATCMR it did not occur (0%) (P < 0.02). Thus, in both groups graft loss due to IF/TA was significantly higher in patients who experienced ATCMRs.
We then examined whether ATCMRs had different features in the two groups. The percentage of patients with ATCMRs, the number of rejections and their histological severity were not significantly different. However, steroid resistant ATCMRs were observed in group 2 (P< 0.01) whereas lateATCMR occurred in group 1 (P < 0.03) (Table II) late ATCMRs (100%) occurred in patients who suffered graft loss due to IFITA, while only two of the 15 early ATCMRs (13.3%) were associated with graft loss (P < 0.002). An example of interstitial and tubular changes in the pre-transplant biopsy and at the time of graft loss in a patient who experienced a late ATCMR (type IB) is shown in Fig. 2 (A and B) .
In all group 1 biopsies and in all but one biopsy of group 2, C4d deposition was evaluated. C4d positive staining was not observed in group 1. In contrast, in group 2 C4d positivity was found in 4 cases. The biopsy of a steroid-resistant early ATCMR showed diffuse positivity with glomerulitis, and PTC score was 1 with monocytes predominating ( Fig. 3 A and B) . Focal positivity was observed in three early ATCMRs; glomerulitis was observed in two cases, PTC score was 0 in one case and 1 in two cases, with monocytes predominating, and two cases were steroid resistant.
Evaluation ofclinical data and outcome
Mean serum creatinine levels at six months and one year in the two groups were not significantly different (group 1 = 141.4 ± 48.3 JlM/L, 129.7 ± 49.1 JlM/L vs group 2 = 126.6 ± 42.4 JlM/L, 122.4 ± 49.1 JlM/L). As above-mentioned, however, in group 1 both at six month and one year after transplant, patients with ATCMRs had mean serum creatinine levels significantly higher than those of patients without ATCMRs (Fig. 1) . In contrast, one year after transplant, patients of group 2 with and without rejections had similar mean serum creatinine levels (Fig. 1) .
In group 1 graft loss occurred in 6/28 patients (21.4%), which was due to IF/TA in three cases, thrombosis of renal veins in one case, and cardiovascular diseases in two cases (death with functioning graft), OR = 1.81 (95%CI 1.02-3.21). In 
DISCUSSION
Marginal kidneys are an important option to expand the donor pool. Kidneys from elderly donors may have a reduced renal reserve, and chronic CItoxicity can further impair their function. Sirolimus, administered alone to animals, was devoid of nephrotoxicity, (20) (21) and, when included in Cl-sparing and CI-free protocols, preserved renal function in humans (16) . In previous reports on single kidney transplant recipients from standard donors, when sirolimus was added to CIs the number of ATCMRs was lower than that observed using CI-based protocols (22) . In the absence of CIs, however, it was similar or higher (23-24) depending on number, type and doses of the other irnmunosupressive drugs used in combination with sirolimus (25) (26) 16) .
Tubulo-interstitial ATCMR is the most frequent type of acute rejection (1) (2) (3) (4) (5) (6) . We have studied its features in groups of dual kidney transplant recipients on different immunosuppressive protocols. Mean serum creatinine levelsand graft loss due to IFITA were significantly higher for patients with ATCMRs in both groups, thus, irrespective of the immunosuppressive therapy ATCMRs were detrimental.
The percentage of patients with ATCMRs, the number of rejections and their histological severity were not significantly different. However, late rejections were present only in the group of patients treated with CI-based therapy, and, as reported for single kidney transplant patients (6, (27) (28) , were significantly associated with IF/TA development.
In our study, steroid resistant ATCMRs were observed only in patients treated with CI-free therapy, however, with the exception of one patient who experienced graft loss due to vascular rejection, all patients underwent rejection reversal and their graft is currently functional.
Withdrawal of calcineurin inhibitors has been found to be associated with an increased incidence of antibody-mediated acute rejections (29) (30) . Interestingly, C4d deposition was observed only in ATCMR biopsies ofCI-free patients (group 2).
In group 1,mean serum creatinine levels ofpatients with ATCMRs were significantly higher than those of patients without ATCMRs both at six months and one year after transplant, whereas, CI-free patients with or without ATCMR (group 2), at one year, had similar mean serum creatinine levels. Moreover, in group 1, despite the absence of steroid-resistant rejections, more graft losses were observed. Notably, in both groups graft losses due to IFITA occurred within the third year after transplant, thus the higher number of losses in group 1 was not attributable to differences in follow-up time. These results suggest that the CI-free protocol exhibited lower nephrotoxicity, although a greater number of patients is needed to determine the advantages ofCI-free therapy.
In conclusion, dual kidney transplant recipients from elderly donors on CI-based and CI-free immunosuppressive protocols experienced ATCMRs showing different features. Irrespective of the type of immunosuppression, ATCMRs were associated with a poor prognosis. Thus, a tailored approach for patients on different immunosuppression should be useful for prevention and treatment of acute rejections.
